 Proactive Investors UK | Fusion IP high on drug success ShareCast Diurnal is attempting to develop Chronocort, a modified release therapy that delivers hydrocortisone in a manner that mimics the body's normal circadian rhythm (the body's natural 24-hour hormone cycle). Often patients require lifelong treatment and ... Fusion IP plc : Fusion portfolio company 'Diurnal', announces successful ... |
